All-trans retinoic acid enhances the effect of 5-aza-2′-deoxycytidine on p16INK4a demethylation, and the two drugs synergistically activate retinoic acid receptor β gene expression in the human erythroleukemia K562 cell line

Oncology Letters

Volumn 8, Issue 1, 2014, Pages 117-122

  Xiang, Lili ^a   Dong, Weimin ^a   Wang, Rong ^a   Wei, Jiang ^a   Qiu, Guoqiang ^a   Cen, Jiannong ^b   Chen, Zixing ^b   Zheng, Xiao ^a   Hu, Shaoyan ^c   Xie, Xiaobao ^a   Cao, Xiangshan ^a   Gu, Weiying ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c CHILDREN S HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

5 aza 2 deoxycytidine; All trans retinoic acid; DNA methylation; K562 cells; P16INK4a; Retinoic acid receptor

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CD11B ANTIGEN; CD33 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MICROSOMAL AMINOPEPTIDASE; RETINOIC ACID; RETINOIC ACID RECEPTOR BETA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DEMETHYLATION; ERYTHROLEUKEMIA; GENE; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; K562 CELL LINE; P16INK4A GENE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RETINOIC ACID RECEPTOR BETA GENE; RNA EXTRACTION; TUMOR SUPPRESSOR GENE; UPREGULATION; WESTERN BLOTTING;

EID: 84901237166     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2133     Document Type: Article

References (17)

1. Issa J, Vertino PM, Boehm CD, et al: Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc Natl Acad Sci USA 93: 11757-11762, 1996.
2. Melki JR and Clark SJ: DNA methylation changes in leukaemia. Semin Cancer Biol 12: 347-357, 2002.
3. Takai D, Gonzales FA, Tsai YC, et al: Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer. Hum Mol Genet 10: 2619-2626, 2001.
4. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al; International Vidaza High-Risk MDS Survival Study Group: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10: 223-232, 2009.
5. Steensma DP, Baer MR, Slack JL, et al: Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 27: 3842-3848, 2009.
6. Voso MT, Santini V, Finelli C, et al: Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 15: 5002-5007, 2009.
7. Merlo A, Herman JG, Mao L, et al: 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692, 1995.
8. Herman JG, Jen J, Merlo A and Baylin SB: Hypermeth-ylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 56: 722-727, 1996.
9. Côté S, Sinnett D and Momparler RL: Demethylation by 5-aza-2'-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells. Anticancer Drugs 9: 743-750, 1998.
10. Breitman TR, Selonick SE and Collins SJ: Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 77: 2936-2940, 1980.
11. Honma Y, Takenaga K, Kasukabe T and Hozumi M: Induction of differentiation of cultured human promyelocytic leukemia cells by retinoids. Biochem Biophys Res Commun 95: 507-512, 1980.
12. Momparler RL, Bouchard J and Samson J: Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2'-deoxycytidine. Leuk Res 9: 1361-1366, 1985.
13. Liu Z, Zhang L, Ding F, et al: 5-Aza-2'-deoxycytidine induces retinoic acid receptor-beta(2) demethylation and growth inhibition in esophageal squamous carcinoma cells. Cancer Lett 230: 271-283, 2005.
14. Miasaki FY, Vivaldi A, Ciampi R, et al: Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'treatment. J Endocrinol Invest 31: 724-730, 2008.
15. Aoyama S, Nakano H, Danbara M, et al: The differentiating and apoptotic effects of 2-aza-5'-deoxycytidine are dependent on the PU.1 expression level in PU.1-transgenic K562 cells. Biochem Biophys Res Commun 420: 775-781, 2012.
16. Herman JG, Civin CI, Issa JP, et al: Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57: 837-841, 1997.
17. Uenogawa K, Hatta Y, Arima N, et al: Azacitidine induces demethylation of p16INK4a and inhibits growth in adult T-cell leukemia/lymphoma. Int J Mol Med 28: 835-839, 2011.